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A B S T R A C T
Introduction: The age of diagnosis of Huntington's disease (HD) varies among individuals with the same HTT
CAG-repeat expansion size. We investigated whether early-life events, like perinatal insults or neurodevelop-
mental disorders, influence the diagnosis age.
Methods: We used data from 13,856 participants from REGISTRY and Enroll-HD, two large international mul-
ticenter observational studies. Disease-free survival analyses of mutation carriers with an HTT CAG repeat ex-
pansion size above and including 36 were computed through Kaplan-Meier estimates of median time until an HD
diagnosis. Comparisons between groups were computed using a Cox proportional hazard survival model ad-
justed for CAG-repeat expansion length. We also assessed whether the group effect depended on gender and the
affected parent.
Results: Insults in the perinatal period were associated with an earlier median age of diagnosis of 45.00 years
(95%CI: 42.07–47.92) compared to 51.00 years (95%CI: 50.68–51.31) in the reference group, with a CAG-
adjusted hazard ratio of 1.61 (95%CI: 1.26–2.06). Neurodevelopmental disorders were also associated with an
earlier median age of diagnosis than the reference group of 47.00 years (95% CI: 43.38–50.62) with a CAG-
adjusted hazard ratio of 1.42 (95%CI: 1.16–1.75). These associations did not change significantly with gender or
affected parent.
Conclusions: These results, derived from large observational datasets, show that perinatal insults and neurode-
velopmental disorders are associated with earlier ages of diagnosis of magnitudes similar to the effects of known
genetic modifiers of HD. Given their clear temporal separation, these early events may be causative of earlier HD
onset, but further research is needed to prove causation.
1. Introduction
Huntington's disease (HD) is a progressive neurodegenerative dis-
ease characterized by motor, cognitive and behavioral symptoms. In
Europe, North America, and Australia the overall prevalence is 5.70
cases per 100,000 [1] and is expected to increase by approximately
15–20% per decade [2]. There is no cure and little evidence to support
symptomatic treatment [3].
The length of the CAG-repeat expansion in the HTT gene (Hugo
Gene Nomenclature ID: 4851) is the largest determinant of the age of
diagnosis of disease, accounting for approximately 67% of the overall
variation [4]. However, there is still substantial variability in the age of
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diagnosis after controlling for repeat expansion length, which by defi-
nition is due to some combination of other genetic or environmental
factors or the interaction between genetic and environmental factors.
Variation in certain loci has been shown to hasten the onset of disease
by up to 6 years or delay it by 1.4–1.6 years [5]. In a large Venezuelan
kindred, as much as 41% of the age of diagnosis variability in HD fa-
milies was attributed to environmental factors not shared by family
members [6]. Identifying environmental modifiers which may be tar-
geted to delay the age of onset in pre-manifest gene expansion carriers
(GEC) is critical to reducing the burden of HD.
The inheritance of an HD mutation initiates a lifelong pathogenic
process, which is eventually followed by symptom onset and clinical
diagnosis [4]. There is growing evidence that key pathological pro-
cesses in HD have their origin early in life [7]. The huntingtin protein
(HTT) is important for neurogenesis and neuronal migration [8], and a
complete loss of HTT function during embryonic development is lethal
[7]. Disruption of HTT function in utero, through reduced expression of
normal HTT, or expressing mutant poly-CAG HTT, alters the mor-
phology of cortical neurons in adulthood and can cause cortical and
striatal degeneration during aging [9,10].
The aim of this study was to determine whether early-life events
alter the natural history of HD. We investigated the association of
perinatal insults and neurodevelopmental disorders with age of diag-
nosis of HD in two large multicenter international longitudinal cohorts
[11,12] using survival analysis methodology. Perinatal insults have
been linked to deficits in functional domains affected in HD, such as
cognition, locomotion, behavior or sensory development in approxi-
mately 40% of survivors in the general population [13]. We further
examined whether associations depend on the gender of the partici-
pants or the gender of the affected parent, since it is possible that these
may influence any relationship with early life events and age of diag-
nosis in HD. The gender of the affected parent may have an effect on
age of diagnosis in HD in two ways: the CAG-repeat expansion is more
likely to further expand during transmission from an affected father,
which decreases the age of onset in his offspring [14]. Alternately, it
could also be hypothesized that GEC whose mothers were also carriers
of the abnormal gene might have experienced effects during embryonic
and fetal development, which were not experienced by GEC that in-
herited the mutated gene from their fathers; and this might exert an
independent effect on HD disease-free survival, either via the perinatal
and neurodevelopmental factors we examined here, or through other
routes. We hypothesized that a perinatal insult and/or a neurodeve-
lopmental disorder, and an HD positive genotype could have additive
damaging effects, which could manifest as an earlier disease diagnosis.
2. Materials and methods
We followed STROBE guidelines for reporting epidemiological re-
sults and SAMPL guidelines for reporting statistical findings according
to the suggested guidelines of the EQUATOR Network.
2.1. Ethical approval and reporting guidelines
This study and its contributing works were performed in accordance
with the declaration of Helsinki and approved by the local ethics
committees for each study site contributing to REGISTRY
(NCT01590589) and Enroll-HD (NCT01574053). All participants gave
informed written consent. Participants lacking consenting capacity had
consent given on their behalf as requested by country-specific ethical
standards. Only data from persons above and including 21 years of age
were included.
2.2. Datasets, study designs, and participants
All participants were part of the European Huntington's Disease
Network's (EHDN) multicenter, European, prospective observational
study – REGISTRY (V2 and V3) [11]; or part of the Enroll-HD (2016
release) [12]. 14,893 participants from 165 study sites in 21 European
countries were enrolled in REGISTRY between 2004 and 2016. Enroll-
HD succeeded REGISTRY and also included participants from North
America, Latin America, and Australasia enrolled between 2012 and
2016. The Enroll-HD 2016 release contained the data of 8714 partici-
pants, including 3598 participants previously enrolled in REGISTRY.
These longitudinal cohorts include manifest and pre-manifest GEC, as
well as healthy controls and individuals at risk of HD. For our analysis,
we only included GEC with: a CAG-repeat expansion length above and
including 36 repeats on the major allele; an age at diagnosis or an age at
last visit above and including 21 years; and available co-morbidities
data. We removed duplicate records from the Enroll-HD participants
who were also enrolled in REGISTRY. This limited the number of par-
ticipants to 7686 manifest GEC and 2069 pre-manifest GEC from
REGISTRY, and 2892 manifest and 1209 pre-manifest GEC from Enroll-
HD. The age of diagnosis of HD variable was present in both databases,
and carried over for the participants in REGISTRY, which were also
included in Enroll-HD, and can thus be presumed to be recorded with
comparable criteria in both studies. Since the variables of interest were
similar between studies, as were the study designs, the two datasets
were combined into one large dataset after excluding duplicate records.
The final dataset for calculating the influence of age at diagnosis in-
cluded the data of 10,578 manifest and 3278 pre-manifest GECs. For a
secondary analysis on the influence of gender of the affected parent on
the model, data were available for 7271 manifest and 3207 pre-man-
ifest GECs. The amounts of participants included in each stage are
shown in the Supplementary Fig. 1.
2.3. Identification of perinatal complications and neurodevelopmental
disorders
Two perinatal investigators (M.B., A.G.) examined all the co-
morbidities listed in each database to identify perinatal insults and
neurodevelopmental disorders. Perinatal insults (MeSH ID: D054238)
were defined as insults which likely occurred between 28 weeks of
gestation to 28 days after birth. Where recorded, the age at the event
and ICD10 codes were used to describe events that occurred during the
neonatal period, as opposed to complications of pregnancy described in
the records of the mother. Dates of the adverse events were not re-
corded for all participants and where recorded, it was sometimes pos-
sible to narrow the insult down to the first year of life but not the first
28 days after birth. Conditions of this kind that were additionally listed
as ‘intrauterine’, ‘perinatal’ or ‘neonatal’ were considered as having
occurred within the perinatal time-frame.
For neurodevelopmental disorders, the co-morbidities records were
screened for neurodevelopmental disorders included in the DSM-5 and
ICD10 classification. This list includes conditions such as neurocogni-
tive disorders, communication and language deficits, autism, and at-
tention deficit hyperactivity disorder. The age-limit for neurodevelop-
mental disorders was set at 20 years and attention deficits above this
age and psychiatric conditions, such as schizophrenia were excluded.
We further looked at medication-use records for methylphenidate (and
brand names) prescribed for ADHD or attention disturbances (and not
for apathy, irritability, somnolence or psychiatric disturbances, etc.)
prior to 20 years of age. We excluded tics and Tourette's syndrome as
these may mimic the symptoms of HD. The list was supplemented with
conditions listed in reviews on the neurodevelopmental outcomes of
perinatal insults [13,15]. Non-specific disorders, which could also have
an adulthood onset, such as seizures, psychiatric complaints, hearing
loss and visual loss, with the exception of the pediatric visual disorder
strabismus, were excluded to limit the statistical noise.
2.4. Statistical analysis
To determine participants' age of diagnosis, we used the Kaplan-
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Meier product limit method. A single estimate of the age of diagnosis in
years (median and 95% confidence interval [95% CI]) was derived for
each group of participants for each of the databases. For pre-manifest
GECs, we used the latest visit date in their profile as an age of diagnosis-
free survival. The primary analysis was done with the merged and de-
duplicated dataset, and secondary sensitivity analyses were done with
REGISTRY and Enroll-HD datasets independently.
The associations of perinatal insults and neurodevelopmental dis-
orders with HD age of diagnosis were adjusted for CAG-repeat expan-
sion length on the major allele through a Cox proportional hazards
model. The assumption for the proportionality of hazard ratios (HR)
was tested with Schoenfeld residuals and with time-dependent covari-
ates. The overall proportional hazard assumption was not violated for
analyzing time until diagnosis by the group, as the time-dependent
covariates (p=0.385), as well as Schoenfeld residuals, were not sig-
nificant (all p= 0.188). Participants were grouped into three groups:
perinatal insults, neurodevelopmental disorders, and the reference
group consisting of the remaining participants (Tables 1 and 2). HR and
95%CI were generated for each of the groups, compared to the re-
ference group. As a sensitivity measure, we recalculated the HRs in the
individual absence of the most common perinatal insults and neuro-
developmental disorders. Additionally, we investigated whether the
association seen per group depended on the gender of the participant or
the gender of the parent from whom the mutation was inherited. The
merged cohort was used for this analysis. The participant gender info
was available for all participants; however, affected parent data was
only available for a subset (Supplementary Fig. 1). Therefore, we first
performed a multiple imputation (MI) method for the missing values of
an affected parent using all the variables included in the Cox regression
model as a predictor. After the MI, where the maximum number of
iterations was set to 20, 30 complete datasets were created and Cox
regression analysis was applied to each dataset and then pooled. To
assess association modification we calculated interaction terms be-
tween group and gender, and between the group and affected parent in
the model of the CAG adjusted HR. If the interaction term with gender
and/or affected parent was statistically significant, we expressed the
group effect for each level of gender and/or affected parent with the
corresponding CAG-adjusted HR and 95%CI. As a sensitivity analysis,
we also performed the complete case analysis, by applying the same
model to only participants with complete information. We compared
the pooled results after MI to the results from the complete case ana-
lysis.
Two-sided p-values below 0.05 were considered statistically sig-
nificant. Statistical analyses were performed with IBM SPSS Statistics
for Windows (Version 24.0, Armonk, NY).
3. Results
3.1. Description of comorbidities included
In the combined cohort, there were 91 participants with perinatal
insults and 141 participants with neurodevelopmental disorders in-
cluded. Seven cases had both a perinatal insult and a neurodevelop-
mental disorder. The comorbidities included in this study are listed in
Table 1.
3.2. Influence of perinatal insults and neurodevelopmental disorders in
disease-free survival
From the merged cohort, 13,856 GECs were included in our survival
analysis, of which 10,578 had manifest HD and 3278 were pre-manifest
carriers. The baseline characteristics of the reference groups were
homogeneous for REGISTRY and Enroll-HD cohorts, and both were
composed for the great majority of Caucasian participants (Table 2).
The Kaplan Meier survival plot (Fig. 1) showed that both perinatal in-
sults (PI) and neurodevelopmental disorders (ND) had a reduced time
until an HD diagnosis (unadjusted HR's: 1.61 [95% CI: 1.26–2.05], 1.37
[95% CI: 1.11–1.68], respectively; CAG-adjusted HR's: 1.61 [95% CI:
1.27–2.06], 1.42 [95% CI: 1.16–1.75], respectively).
The overall time until diagnosis, characteristics and hazard ratios
for each group are shown in Table 2. The secondary sensitivity analysis
from the REGISTRY cohort confirmed these results for both the peri-
natal insults group and the neurodevelopmental disorders group (CAG-
adjusted HR 1.64 [95% CI: 1.26–2.15], HR 1.63 [95% CI: 1.29–2.05],
respectively). The Enroll-HD cohort showed non-statistically significant
results (CAG-adjusted HR 1.45 [95% CI: 0.80–2.63], HR: 0.24 [95% CI:
0.15–0.39], respectively). We further investigated the relative con-
tributions of specific disorders to the overall association seen. These
Table 1
Description of the comorbidities included from the REGISTRY and Enroll-HD cohorts, divided into perinatal insults and neurodevelopmental disorders. N, the number
of comorbidities; %, the percentage of comorbidities.
Registry % (N) Enroll-HD % (N) Combined percentage %
(N)
Perinatal insults
Birth injury, birth asphyxia, apnea or meconium aspiration 33.78% (25) 17.65% (3) 30.76% (28)
Preterm birth 22.97% (17) 0% (0) 18.68% (17)
Kernicterus 13.51% (10) 5.88% (1) 12.09% (11)
Meningitis, encephalitis 8.11% (6) 17.65% (3) 9.89% (9)
Perinatal hematological disorder, Rh isoimmunization of fetus, transient neutropenia 6.76% (5) 5.88% (1) 6.59% (6)
Others (Acquired periventricular cysts, personal history of conditions arising in perinatal period, atelectasis of
newborn, convulsions, intestinal perforation, hyperthermia, gestational diabetes of mother)
5.41% (4) 17.65% (3) 7.69% (7)
Vomiting/diarrhea/intestinal obstruction 5.41% (4) 0% (0) 4.40% (4)
Congenital infections (bacterial sepsis, congenital hepatitis, congenital herpes) 2.70% (2) 11.76% (2) 4.40% (4)
Hyperthyroidism, hypothyroidism, iodine deficiency 1.35% (1) 11.76% (2) 3.30% (3)
Neonatal cerebral depression 0% (0) 11.76% (2) 2.20% (2)
Total 100% (74) 100% (17) 100% (91)
Neurodevelopmental disorders
Strabismus 50.91% (56) 32.26% (10) 46.81% (66)
Dyslexia, alexia, disorder of scholastic skills, disorders of speech and language 28.18% (31) 16.13% (5) 25.53% (36)
Disturbance of activity and attention with onset below 20 years 7.27% (8) 35.48% (11) 13.48% (19)
Mental retardation 7.27% (8) 6.45% (2) 7.09% (10)
Cerebral palsy 4.55% (5) 3.23% (1) 4.26% (6)
Autism 0.91% (1) 0% (0) 0.71% (1)
Down syndrome 0.91% (1) 0% (0) 0.71% (1)
Emotional disturbances, attachment disorder, and social anxiety 0% (0) 6.45% (2) 1.42% (2)
Total 100% (110) 100% (31) 100% (141)
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analyses indicated that birth trauma and hypoxia, as well as meningitis
or encephalitis, had the largest individual contributions to the overall
association seen in perinatal insults group; however, the increased risk
was still present after excluding these insults. In the neurodevelop-
mental disorders group, the contributions of individual insults to the
overall association were considerably smaller. In this group ADHD and
attention deficits had the largest individual effects on the overall as-
sociation (Supplementary Table 1).
3.3. The association of gender and affected parent with disease-free survival
per group
The overall time until diagnosis of HD by gender and affected parent
is shown in Table 3. The interactions between group and gender, or
group and affected parent were not statistically significant for either
perinatal insults or neurodevelopmental disorders.
4. Discussion and conclusions
In this study, we explored the role of early-life events on the natural
history of HD. Our results showed that perinatal insults and neurode-
velopmental disorders were associated with earlier age of diagnosis of
HD, with an observed unadjusted difference of 4–6 years. These dif-
ferences are substantial since the most robust recently-described ge-
netic modifiers, rs148491145 on chromosome 14 and rs146353869 on
chromosome 15, accelerated the onset of disease by 3.2 and 6.1 years,
respectively [5].
We further investigated the effect of gender or affected parent on
the association, since the infant gender seems to modulate the risk of
adverse outcomes after a perinatal insult in the general population and
the risk of neurodevelopmental disorders [16–18]. The gender of the
affected parent could also play a role through either the genetic an-
ticipation phenomenon, where infants from affected father have a
greater risk of CAG-repeat length expansion and henceforth an early
symptomatic onset [14], or possibly the mother's genetic status may
influence the pregnancy and associated in utero events. Our results
showed that neither of these factors played a significant role in the
overall association.
The accelerated diagnosis associated with perinatal and neurode-
velopmental disorders could imply both biological and social factors.
We speculated that early-life events may speed up the biological onset
of HD through cumulative damage to the striatum and connected re-
gions, which could diminish the neural reserve, accelerate neuro-
pathology or alter neurodevelopment in a way that predisposes to
earlier onset. The basal ganglia have a higher metabolic activity early in
life, which makes this region especially vulnerable [19]. Early-life
events also damage several other brain regions, including regions af-
fected later in the course of HD, such as the cortico-thalamic circuitries
[20], and cause lasting changes in epigenetic regulation of gene ex-
pression that may accelerate neurodegeneration decades later [21].
These biological factors could potentially aggravate the disease
Table 2
Characteristics of the merged cohort, the REGISTRY cohort, and the Enroll-HD
cohort, divided by the group of participants, including sample sizes, gender
ratio, the median age of diagnosis in years, median CAG length, and percentage
and number of Caucasians, Europeans and North Americans. 95%CI, 95%
confidence interval; HR, hazard ratio; IQR, interquartile range; N, the number
of participants; %, the percentage of participants.
Merged cohort REGISTRY Enroll-HD
Reference group
N (N manifest) 13,631 (10,428) 9578 (7566) 4053 (2862)
% male 46.63% 46.82% 46.57%
Median CAG (IQR) 43 (41–45) 43 (41–45) 43 (41–45)
Median age of
diagnosis
(95%CI)
51.00
(50.68–51.32)
50.00
(49.63–50.37)
52.00
(51.43–52.57)
% Caucasian (N) 95.83% (13,062) 97.52% (9340) 90.20% (2656)
% Europe (N) 81.90% (11,164) 100% (9578) 39.13% (1586)
% North-America
(N)
16.00% (2181) 0% (0) 53.81% (2181)
Perinatal insults
N (N manifest HD) 91 (65) 74 (54) 17 (11)
% male 45.05% 47.30% 35.29%
Median CAG (IQR) 44 (42–47) 44 (42–47) 43 (41–44)
Median age of
diagnosis
(95%CI)
45.00
(42.07–47.93)
43.00
(39.84–46.16)
49.00
(43.57–54.43)
% Caucasian (N) 97.80% (89) 97.30% (72) 100% (17)
% Europe (N) 90.11% (82) 100% (74) 47.06% (8)
% North-America
(N)
9.89% (9) 0% (0) 52.94% (9)
CAG-adjusted HR
(95%CI)
1.61 (1.27–2.06) 1.64 (1.26–2.15) 1.45 (0.80–2.63)
Neurodevelopmental disorders
N (N manifest HD) 141 (92) 110 (73) 31 (19)
% male 48.93% 52.72% 35.48%
Median CAG (IQR) 44 (42–46) 44 (42–46) 42 (40–44)
Median age of
diagnosis
(95%CI)
47.00
(43.63–50.37)
45.00
(41.36–48.64)
53.00
(47.30–58.70)
% Caucasian (N) 96.45% (136) 98.18% (108) 90.32% (28)
% Europe (N) 83.69% (118) 100% (110) 25.81% (8)
% North-America
(N)
16.31% (23) 0% (0) 74.19% (23)
CAG-adjusted HR
(95%CI)
1.41 (1.15–1.74) 1.61 (1.28–2.02) 0.24 (0.15–0.39)
Fig. 1. Kaplan-Meier survival curves of the age of diagnosis for the merged cohort. A Participants with perinatal insults versus the “reference” group; B Participants
with neurodevelopmental disorders versus the “reference” group. 95% CI, 95% confidence interval; HR, hazard ratio; Neurodevelopm, neurodevelopmental dis-
orders.
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presentation and lead to earlier diagnosis, but need to be validated in
other experimental models. Despite the clear temporal separation be-
tween perinatal and developmental problems and subsequent HD onset,
our study design did not allow us to assess dose-response, specificity or
experimental evidence from other biological systems, to confirm caus-
ality according to the Bradford Hill's criteria for causality in a biological
system [22].
An alternate hypothesis is that early-life events affect social factors,
such as more frequent interactions with medical care throughout life,
which could lead to a diagnosis in an earlier stage of the disease. Infants
that survive direct birth trauma, such as perinatal asphyxia often have a
spectrum of neurological impairment, ranging from normal functioning
to severe neurological disabilities; like cerebral palsy, attention deficit
hyperactivity disorder (ADHD), autism, congenital hearing loss and
neonatal seizures [13,15]. Preterm birth is commonly associated with
cognitive, behavioral, attentional, or socialization deficits and occa-
sionally with major motor deficits [23]. Preterm birth also increases the
mortality risk in adulthood due to several health risks; including in-
creased rates of diabetes, metabolic syndrome, neuropsychiatric dis-
orders, respiratory, cardiovascular and kidney diseases [24]. All of
these factors may increase the frequency of medical care, in support of
the social theory.
In the general population, perinatal insults are often linked to
neurodevelopmental disorders, such as learning difficulties, cognitive
deficits or a developmental delay in approximately 60% of cases; cer-
ebral palsy (21%); hearing impairment (20%); visual impairment (18%)
or behavioral problems (11%) [13]. However, in HD, neurodevelop-
mental disorders only occurred in seven of the cases with perinatal
insults. This may be due to incomplete reporting of neonatal insults in
the neurodevelopmental group, or due to the multifactorial causes of
neurodevelopmental disorders. Whilst perinatal insults increase the risk
of strabismus, ADHD and dyslexia in the general population [17,25,26],
these disorders are associated with several other environmental and
genetic risk factors [25,27].
Surprisingly, we found a much lower incidence of perinatal insults
in the HD groups than in the general population. The most common
insults in the HD groups were direct birth trauma/asphyxia (with a
prevalence of 0.20%), followed by preterm birth (0.12%), neonatal/
congenital infections and kernicterus. In the general population as-
phyxia-related encephalopathy and preterm birth (before 37 weeks of
gestation) respectively occurred in 0.85% [16] and 11.1% of live births
globally in 2010 [28]. The most common neurodevelopmental dis-
orders in the studied cohorts were strabismus (0.48%), disturbances in
attention or activity (0.14%), and dyslexia or alexia (0.26%). The fre-
quency of these disorders was also markedly lower than in the general
population, where strabismus affects 2–3% [29], and ADHD and de-
velopmental dyslexia both affect around 7% of children below 18 years
[18,30].
Our approach has limitations. The low frequency of perinatal and
neurodevelopmental events in the studied cohorts may indicate that HD
participants with additional comorbidities are less inclined to partici-
pate in research (selection bias), in addition to a possible recall bias due
to difficulties in retrospectively assessing events which occurred several
years before enrollment. Despite our use of a robust survival analysis,
we could not eliminate the effects of these apparent biases, and the true
effect of these insults may be smaller or larger than our study design
could detect. The recall bias and relative rareness of these conditions
meant that we had to combine perinatal insults and neurodevelop-
mental disorders that affect several divergent functional domains - such
as language, attention, locomotion and cognition - into two main
groups. These conditions are associated with dysfunction in several
brain regions, and some conditions are hypothesized to be more det-
rimental to HD GECs than others. We assessed the relative contribution
of some of the exposures to the overall association and conclude that
birth trauma/hypoxia and meningitis/encephalitis had a larger con-
tribution to the overall increase in risk than preterm birth or ker-
nicterus. In the neurodevelopmental disorders ADHD had the largest
effect, but the effect of individual insults on the overall hazard ratio was
small. ADHD may mimic the earliest symptoms of HD, and thus we only
included cases where ADHD was reported before 20 years. This was
well before the average age of diagnosis of 47 years in the neurode-
velopmental disorders group, and presumably the ADHD in these cases
represented the neurodevelopmental disorder and not an early mani-
festation of HD. The association with neurodevelopmental disorders
was not replicated in the Enroll-HD cohort, likely due to insufficient
sample size and divergent participant characteristics. Despite these
limitations, here we provide the first clinical association of early-life
events with HD age of diagnosis.
In conclusion, this work shows that perinatal and neurodevelop-
mental insults associate with an earlier age at diagnosis of HD, with an
Table 3
Survival differences by gender and affected parent per group, including sample sizes, gender ratio, the median age of diagnosis in years, and median CAG length.
95%CI, 95% confidence interval; IQR, interquartile range; N, the number of participants.
Reference Perinatal insults Neurodevelopmental disorders
Effect of gender of participant on overall survival per group
Males
N (N manifest HD) 6356 (5093) 41 (30) 69 (46)
Median age of diagnosis (95%CI) 50.00 (49.57–50.44) 43.00 (40.45–45.55) 48.00 (43.76–52.24)
Median CAG (IQR) 43 (4) 44 (4.5) 43 (5)
Females
N (N manifest HD) 7275 (5335) 50 (35) 72 (46)
Median age of diagnosis (95%CI) 51.00 (50.54–51.55) 47.00 (44.26–49.75) 47.00 (43.09–50.91)
Median CAG (IQR) 43 (4) 43 (5.25) 44 (4)
Comparison between genders
p-value – 0.537 0.799
Effect of gender of affected parent on overall survival per group
Affected father
N (N manifest HD) 4747 (3476) 29 (22) 55 (34)
Median age of diagnosis (95%CI) 49.00 (48.46–49.54) 43.00 (41.50–44.50) 42.00 (34.67–49.33)
Median CAG (IQR) 43 (4) 44 (6) 44 (5)
Affected mother
N (N manifest HD) 5359 (3675) 45 (27) 63 (37)
Median age of diagnosis (95%CI) 51.00 (50.47–51.53) 48.00 (41.02–54.98) 47.00 (44.11–49.89)
Median CAG (IQR) 43 (4) 44 (5) 43 (5)
Comparison between affected parent
p-value (complete case analysis) – 0.699 0.977
p-value (multiple imputation) – 0.791 0.874
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effect comparable to that seen with known genetic modifiers. Further
research is needed into the basis and mechanisms of this association to
prove causation. These observations emphasize the far-reaching impact
of early-life events in adult onset neurodegeneration.
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